Literature DB >> 17940966

In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.

Hideki Ebihara1, Steven Theriault, Gabriele Neumann, Judie B Alimonti, Joan B Geisbert, Lisa E Hensley, Allison Groseth, Steven M Jones, Thomas W Geisbert, Yoshihiro Kawaoka, Heinz Feldmann.   

Abstract

To facilitate an understanding of the molecular aspects of the pathogenesis of Zaire ebolavirus (ZEBOV) infection, we generated 2 different recombinant viruses expressing enhanced green fluorescent protein (eGFP) from additional transcription units inserted at different positions in the virus genome. These viruses showed in vitro phenotypes similar to that of wild-type ZEBOV (wt-ZEBOV) and were stable over multiple passages. Infection with one of the viruses expressing eGFP produced only mild disease in rhesus macaques, demonstrating a marked attenuation in this animal model. However, in mice lacking signal transducer and activator of transcription 1, both viruses expressing eGFP caused lethal cases of disease that were moderately attenuated, compared with that caused by wt-ZEBOV. In mice, viral replication could be easily tracked by the detection of eGFP-positive cells in tissues, by use of flow cytometry. These findings demonstrate that the incorporation of a foreign gene will attenuate ZEBOV in vivo but that these viruses still have potential for in vitro and in vivo research applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940966     DOI: 10.1086/520590

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

2.  Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Authors:  Kristina Maria Schmidt; Michael Schümann; Judith Olejnik; Verena Krähling; Elke Mühlberger
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.

Authors:  Manu Anantpadma; Jennifer Kouznetsova; Hang Wang; Ruili Huang; Andrey Kolokoltsov; Rajarshi Guha; Aaron R Lindstrom; Olena Shtanko; Anton Simeonov; David J Maloney; Wendy Maury; Douglas J LaCount; Ajit Jadhav; Robert A Davey
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA.

Authors:  Claire Marie Filone; Ken Dower; Glenn S Cowley; Lisa E Hensley; John H Connor
Journal:  Assay Drug Dev Technol       Date:  2015-02-03       Impact factor: 1.738

5.  Gamma Irradiation as an Effective Method for Inactivation of Emerging Viral Pathogens.

Authors:  Friederike Feldmann; W Lesley Shupert; Elaine Haddock; Barri Twardoski; Heinz Feldmann
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

Review 6.  Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.

Authors:  Darryl Falzarano; Allison Groseth; Thomas Hoenen
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

7.  High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.

Authors:  Megan R Edwards; Colette Pietzsch; Thibaut Vausselin; Megan L Shaw; Alexander Bukreyev; Christopher F Basler
Journal:  ACS Infect Dis       Date:  2015-06-24       Impact factor: 5.084

8.  Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.

Authors:  James E Strong; Gary Wong; Shane E Jones; Allen Grolla; Steven Theriault; Gary P Kobinger; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Authors:  Jason S Richardson; Michel K Yao; Kaylie N Tran; Maria A Croyle; James E Strong; Heinz Feldmann; Gary P Kobinger
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.